Xencor (XNCR) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xencor (XNCR) has outperformed Zai Lab (ZLAB) over the past year, gaining 109.6% versus a gain of 5.0%. Over five years, XNCR leads with a -6.2% price change compared with -72.7% for ZLAB. Zai Lab is the larger company by market cap ($2.63 billion vs $2.50 billion), about 1.1 times the size.
Zai Lab converts more of its revenue into profit, with a net margin of -38.1% versus -73.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XNCR | ZLAB |
|---|---|---|
| Share price | $33.26 | $21.03 |
| Market cap | $2.50B | $2.63B |
| 1-day change | -2.21% | -4.06% |
| YTD return | +117.24% | +19.22% |
| 1-year return | +109.58% | +5.04% |
| 5-year return | -6.15% | -72.67% |
| EPS (TTM) | $-1.56 | $-1.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $125.58M | $460.16M |
| Revenue growth (YoY) | +13.65% | +15.33% |
| Net income (latest FY) | $-91.92M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | -141.35% | -49.86% |
| Net margin | -73.20% | -38.15% |
| 52-week high | $40.60 | $29.02 |
| 52-week low | $10.38 | $15.96 |
| Distance from 52-week high | -18.08% | -27.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +27.78% | +62.67% |
| Average volume | 1.54M | 991.34K |
| Shares outstanding | 75.04M | 124.84M |
| Employees | 260 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed ZLAB by 104.5 percentage points over the past year.
- Zai Lab is more profitable, keeping -38.1 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
XNCR vs ZLAB FAQ
Which is bigger, Xencor or Zai Lab?
Zai Lab (ZLAB) is larger, with a market capitalization of $2.63B compared with $2.50B for Xencor (XNCR).
Which stock has performed better over the past year, XNCR or ZLAB?
XNCR returned +109.58% over the past 12 months, compared with +5.04% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Xencor and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.